1270017-96-3

Upstream product

• 1270017-94-1 C₄₈H₄₄ClNO₆S 
• 1352714-49-8 C₄₃H₄₀ClNO₇S 

Downstream Products

• 1270018-49-9 (2S,3R,4R,5S,6S)-2-(4-chloro-3-((5-(furan-2-yl)thiazol-2-yl)methyl)phenyl)-6-(1-hydroxycyclopropyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1270018-45-5 (2S,3S,4R,5R,6S)-methyl 6-(4-chloro-3-((5-(furan-2-yl)thiazol-2-yl)methyl)phenyl)-3,4,5-trihydroxy-tetrahydro-2H-pyran-2-carboxylate 
• 1270017-98-5 (2S,3S,4R,5S,6S)-3,4,5-tris(benzyloxy)-6-(4-chloro-3-((5-(furan-2-yl)thiazol-2-yl)methyl)phenyl)-tetrahydro-2H-pyran-2-carbaldehyde 
• 1270018-00-2 2-(2-chloro-5-((2S,3S,4R,5S,6S)-3,4,5-tris(benzyloxy)-6-(difluoromethyl)-tetrahydro-2H-pyran-2-yl)benzyl)-5-(furan-2-yl)thiazole 
• 1270018-02-4 1-((2R,3S,4R,5S,6S)-3,4,5-tris(benzyloxy)-6-(4-chloro-3-((5-(furan-2-yl)thiazol-2-yl)methyl)phenyl)-tetrahydro-2H-pyran-2-yl)ethanol 
• 1270018-04-6 C₄₃H₄₀ClNO₆S 
• 1270018-08-0 (2S,3S,4R,5S,6S)-3,4,5-tris(benzyloxy)-6-(4-chloro-3-((5-(furan-2-yl)thiazol-2-yl)methyl)phenyl)-tetrahydro-2H-pyran-2-carboxylic acid 
• 1270018-10-4 (2S,3S,4R,5S,6S)-methyl 3,4,5-tris(benzyloxy)-6-(4-chloro-3-((5-(furan-2-yl)thiazol-2-yl)methyl)phenyl)-tetrahydro-2H-pyran-2-carboxylate 
• 1270018-12-6 2-((2S,3S,4R,5S,6S)-3,4,5-tris(benzyloxy)-6-(4-chloro-3-((5-(furan-2-yl)thiazol-2-yl)methyl)phenyl)-tetrahydro-2H-pyran-2-yl)propan-2-ol 
• 1270018-14-8 1-((2S,3S,4R,5S,6S)-3,4,5-tris(benzyloxy)-6-(4-chloro-3-((5-(furan-2-yl)thiazol-2-yl)methyl)phenyl)-tetrahydro-2H-pyran-2-yl)cyclopropanol 

Relevant academic research and scientific papers

THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2

In order to investigate SAR regarding glucose moiety in novel C-aryl glucoside SGLT2 inhibitors containing a thiazole motif, a series of chemical modifications on glucose was conducted to explore potential utility as a suitable replacement of glucose per